Schrödinger (SDGR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 22, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online and vote in advance or during the meeting.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting: Richard A. Friesner, Rosana Kapeller-Libermann, and Gary Sender.
Advisory vote on executive compensation is up for approval.
Proposal to amend the 2022 Equity Incentive Plan to increase available shares by 3,000,000.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Schrödinger
- Q1 2026 saw 12% ACV growth, strong drug discovery revenue, and a major M&A milestone.SDGR
Q1 20266 May 2026 - Board recommends approval of all proposals, including director elections and equity plan amendment.SDGR
Proxy filing28 Apr 2026 - 23% revenue growth to $255.9M, strong cash, and shift to hosted software drive future profitability.SDGR
Q4 202515 Apr 2026 - Strategic shift to hosted software, AI integration, and new products drive growth and industry impact.SDGR
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Transition to ACV, new product launches, and materials science drive growth outlook.SDGR
Leerink Global Healthcare Conference 202610 Mar 2026 - Transition to hosted services and AI-driven innovation drive growth and partnerships in drug discovery.SDGR
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q1 saw strong software growth, clinical progress, and advancing predictive tox initiatives.SDGR
Jefferies Global Healthcare Conference 20253 Feb 2026 - All proposals passed, with strategic focus on clinical milestones and platform expansion.SDGR
AGM 20243 Feb 2026 - Q2 revenue up 35% to $47.3M; predictive toxicology and clinical pipeline drive growth.SDGR
Q2 20242 Feb 2026